Drug Zometa helps fight breast cancer spread

"A drug to prevent bone loss during breast cancer treatment also substantially cut the risk that the cancer would return, results that left doctors excited about a possible new way to fight the disease. It is the first large study to affirm wider anti-cancer hopes for Zometa...

Johnson & Johnson Pain Patch Recall - J&J sais Leak Can Cause Accidental Over...

"Recall Alert: February 13, 2008 Johnson & Johnson announced that it and Novartis AG's Sandoz unit are recalling patches comprising of  fentany because of possible cuts in the drug reservoir that could cause a leak and expose people.The patches are produced by...

Novartis to cut 2,500 jobs worldwide

"Swiss drugmaker Novartis said it plans to cut 2,500 global jobs in a restructuring programme aimed at generating yearly cost savings of $1.6bn (€1.08bn). Novartis currently employs more than 600 people in its manufacturing facility in Ringaskiddy, Co Cork, and its ethical...

Euro RSCG Worldwide named largest global advertising agency 2nd yr

"Of the Top 100 Global Marketers listed in the report, Euro RSCG Worldwide handles advertising for 32 of these brands including Ford Motor Co., Reckitt Benckiser, Danone Group, PSA Peugeot Citroen, Citigroup, Bayer, Schering-Plough Corp., Carrefour, ExxonMobil, Kraft, IBM,...

Man blames health drink for unwanted erection

"NEW YORK - A man has sued the maker of the health drink Boost Plus, claiming the vitamin-enriched beverage gave him an erection that would not subside and caused him to be hospitalized. The lawsuit filed by Christopher Woods of New York said he bought the nutrition beverage...

FDA Approves Patch to Treat Dementia

"The first skin patch to treat the dementia that can plague Alzheimer's patients gained federal approval, a drug company said Monday. The drug in the patch, called Exelon or rivastigmine, is the same as that now available in capsule form but provides a regular and continuous...

MS drug treatment shows promise (AP)

" EAST HANOVER, N.J. - Novartis Pharmaceuticals Corp., the U.S. unit of Swiss drugmaker Novartis AG, said Thursday that at least three out of four patients given an experimental multiple sclerosis treatment were free of relapses for more than two years. The company released...